Lincoln Electric Announces 5.6% Dividend Increase
Get Alerts LECO Hot Sheet
Join SI Premium – FREE
29th Consecutive Annual Dividend Increase
CLEVELAND--(BUSINESS WIRE)-- Lincoln Electric Holdings, Inc., (Nasdaq: LECO) announced today that its Board of Directors has approved a 5.6% increase in the quarterly cash dividend to $0.75 per share, or $3.00 per share on an annualized basis. The dividend is payable January 15, 2025, to shareholders of record at the close of business on December 31, 2024.
“Our dividend increase reflects strong cash flow generation of the business, solid execution of our Higher Standard 2025 Strategy, and confidence in our ability to continue to deliver superior long-term value for our shareholders through the cycle,” stated Steven B. Hedlund, President and Chief Executive Officer.
About Lincoln Electric
Lincoln Electric is the world leader in the engineering, design, and manufacturing of advanced arc welding solutions, automated joining, assembly and cutting systems, plasma and oxy-fuel cutting equipment, and has a leading global position in brazing and soldering alloys. Lincoln is recognized as the Welding Expert™ for its leading materials science, software development, automation engineering, and application expertise, which advance customers’ fabrication capabilities to help them build a better world. Headquartered in Cleveland, Ohio, Lincoln has 71 manufacturing locations in 21 countries and a worldwide network of distributors and sales offices serving customers in over 160 countries. For more information about Lincoln Electric and its products and services, visit the Company’s website at https://www.lincolnelectric.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241017835973/en/
Amanda Butler
Vice President, Investor Relations & Communications
Tel: 216.383.2534
Email: [email protected]
Source: Lincoln Electric Holdings, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 2026
- Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European
- Dr. Ricardo Schwarcz Scholarship for Healthcare Sciences Opens National Opportunity for Undergraduate Students
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share